The biotechnology sector is currently at a critical crossroads, marked by rapid technological advancements and significant economic challenges. The integration of artificial intelligence (AI) into research and development (R&D) processes has become an essential strategic lever to overcome the obstacles posed by the "patent cliff," which threatens to reduce industry revenues by $400 billion. Recent initiatives, such as BioNTech's acquisition of InstaDeep for £562 million and NVIDIA's commitment to generative AI, illustrate the transformative potential of these technologies.